2021 - ESSA Pharma

Date	Title
May 25, 2021	ESSA Pharma to Present at the Jefferies Virtual Healthcare Conference
May 6, 2021	ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2021
April 28, 2021	ESSA Pharma Announces Clinical Collaboration Agreement with Bayer to Evaluate the Combination of EPI-7386 and Darolutamide in Patients with Metastatic Castration-Resistant Prostate Cancer
April 14, 2021	ESSA Pharma to Present at the Bloom Burton & Co. Healthcare Investor Conference
April 10, 2021	ESSA Pharma Presents Preclinical Data Supporting the Therapeutic Potential of EPI-7386 at the 2021 American Association of Cancer Research
March 26, 2021	ESSA Announces Change to its Board of Directors
March 4, 2021	ESSA Pharma Announces Exercise of Option in Connection with Recently Completed $130 Million Financing
February 25, 2021	ESSA Pharma Inc. Reports Results of Annual General & Special Meeting of Shareholders
February 25, 2021	ESSA Pharma to Present at Upcoming March Investor Conferences
February 25, 2021	ESSA Pharma Announces Clinical Collaboration with Astellas to Evaluate the Combination of EPI-7386 and Enzalutamide for Patients with Metastatic Castration-Resistant Prostate Cancer